J&J Medical Connect
RYBREVANT FASPRO™

(amivantamab and hyaluronidase-lpuj)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj)

Patient Medical Information

What Should I Tell My Healthcare Provider Before Receiving RYBREVANT FASPRO?

Last Updated: 12/18/2025

summary

The following content from the RYBREVANT FASPRO PATIENT INFORMATION may be helpful to address your question:

What should I tell my healthcare provider before receiving RYBREVANT FASPRO?

Before you receive RYBREVANT FASPRO, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of lung or breathing problems, other than cancer.1
  • are pregnant or plan to become pregnant. RYBREVANT FASPRO can harm your unborn baby.1
    • Females who are able to become pregnant:
      • Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT FASPRO.
      • You should use effective birth control (contraception) during treatment and for   3 months after your last dose of RYBREVANT FASPRO.
      • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT FASPRO.
  • are breastfeeding or plan to breastfeed. It is not known if RYBREVANT FASPRO passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT FASPRO.1

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.1

Do not receive RYBREVANT FASPRO if you are allergic to hyaluronidase or any of the ingredients in RYBREVANT FASPRO.1

ADDITIONAL INFORMATION

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT INFORMATION for RYBREVANT FASPRO.1

 

References

1 RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT+Faspro-pi.pdf